Aclarion Secures Second Weill Cornell Agreement for Two-Year Nociscan and BMAC Trial
ACON•Aclarion has secured a second commercial agreement deploying its Nociscan platform in a two-year randomized trial at Weill Cornell Medicine under IRB Protocol No. 24-09027977 led by Dr. Härtl. The trial will compare microdiscectomy with and without intradiscal bone marrow aspirate concentrate injection, tracking disc hydration and Nociscan-identified pain biomarkers.
1. Commercial Expansion at Weill Cornell Medicine
Aclarion has established its second commercial agreement with Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center, bringing the Nociscan platform to a leading spine care center. This collaboration, led by Dr. Roger Härtl, operates under IRB Protocol No. 24-09027977 and spans a two-year prospective study.
2. Two-Year Randomized Trial Details
The prospective randomized controlled trial will evaluate lumbar microdiscectomy with and without intradiscal bone marrow aspirate concentrate injection. Key endpoints include intervertebral disc hydration, chemical pain biomarkers quantified by Nociscan and patient-reported outcomes over the 24-month follow-up period.
3. Platform Capabilities and Market Impact
Nociscan leverages magnetic resonance spectroscopy, proprietary signal processing and augmented intelligence algorithms to noninvasively distinguish painful and nonpainful discs. With approximately 266 million people affected by degenerative disc disease worldwide and a reported 97% surgical success rate when treating Nociscan-identified pain-positive discs, the platform aims to optimize clinical decision-making and boost treatment success rates.
